Lyra Therapeutics, Inc. (LYRA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol LYRA
- Company Lyra Therapeutics, Inc.
- Price $0.2
- Changes Percentage 1900
- Change 0.19
- Day Low $0
- Day High $0.52
- Year High $8.75
- Year Low $0
- Market Cap $710
- Price Avg 50 EMA (D) $0.48
- Price Avg 200 EMA (D) $1.44
- Exchange OTC
- Volume 5,469
- Average Volume 9,941
- Open $0
- Previous Close $0.01
- EPS -6.89
- PE 0.00
- Earnings Announcement 2026-08-21 12:00:00
- Shares Outstanding $1,774,882
Company brief: LYRA THERAPEUTICS, INC. (LYRA )
- Healthcare
- Biotechnology
- Dr. Maria Palasis Ph.D.
- https://lyratherapeutics.com
- US
- N/A
- 05-01-2020
- US55234L1052
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.